A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid

Upsala Journal of Medical Sciences

Volumn 116, Issue 2, 2011, Pages 148-154

  Lampon, Natalia ^a   Tutor, J Carlos ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

APRI; butyrylcholinesterase; copper deficiency; FIB 4; non alcoholic fatty liver disease; valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; COPPER; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIOAVAILABILITY; BLOOD; EPILEPSY; FATTY LIVER; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; COPPER; EPILEPSY; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; SPECTROPHOTOMETRY, ATOMIC; VALPROIC ACID; YOUNG ADULT;

EID: 79954455540     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2010.545898     Document Type: Article

References (43)

1. Gertsner T, Bell N, Köning S. Oral valproic acid for epilepsylong term experience in therapy and side effects. Expert Opin Pharmacother. 2008;9:285-92. (Pubitemid 351233735)
2. Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci. 2009;30: 509-14.
3. Chateviaux S, Morceau F, Dicato M, Diederich. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010;2010:pii 479364.
4. Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, et al. Cytometric analysis for druginduced steatosis in HepG2 cells. Chem Biol Interact. 2009; 181:417-23.
5. Cotariu D, Zaldman JL. Valproic acid. Clin Chem. 1988;34: 890-7.
6. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and non-alcoholic liver disease. Ann Neurol. 2004;55:729-32. (Pubitemid 38544334)
7. Luef G, Rauchenzauner M, Waldmann M, Sturn W, Sandhofer A, Seppi K, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009;86:42-7.
8. Aires CCP, Ijlst L, Stet F, Prip-Buus C, Tavares de Almeida I, Duran M, et al. Inhibition of hepatic palmitoyl-trasnferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol. 2010;79: 792-9.
9. Tutor-Crespo MJ, Hermida J, Tutor JC. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring the specific oxidase activity of ceruloplasmin. Epilepsy Res. 2003;56:147-53. (Pubitemid 37464927)
10. Kuzuya T, Amioka K, Nabeshima T. Valproic acid increases biliary copper excretion in the rat. Epilepsy Res. 2002;51: 279-85. (Pubitemid 35232573)
11. Lampón N, Tutor JC. Effect of valproic acid treatment on copper availability in adult epileptic patients. Clin Biochem. 2010;43:1074-8.
12. Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, et al. Copper availability contributes to iron perturbations in human non-alcoholic fatty liver disease. Gastroenterol. 2008;135:680-8.
13. Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A, et al. A role for low hepatic copper concentrations in non-alcoholic fatty liver disease. Am J Gastroenterol. 2010;105:1978-85.
14. Geubel AP, Gregoire V, Rahier J, Lissens W, Dive C. ypoceruloplasminemia and ultrastructural changes resembling Wilson's disease in non-alcoholic liver steatosis. A clinical and pathological study of five cases. Liver. 1988;8:299-306.
15. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-7. (Pubitemid 36733754)
16. Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonografic characteristics. Int J Clin Exp Med. 2010;3:202-10.
17. Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal Studies. J Gastroenterol. 2007;42:97-103.
18. de Abreu MRA, Ramos APP, Vendramini RC, Brunetti IL, Pepato MT. Steatosis and hepatic markers before and shortly after bariatric surgery. Ann Clin Biochem. 2007;44:63-9. (Pubitemid 46168803)
19. Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology. 2010;51:715-17.
20. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Gastroenterology. 2010;52:913-24.
21. Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y, et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986;8:599-602. (Pubitemid 17180569)
22. Iwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med. 2007;46:1633-9.
23. Louro MO, Tutor JC. Determinación de la actividadoxidásica de la ceruloplasmina en los analizadoresCobas Bio y Cobas- Fara. Acta Bioquim Clin Latinoam. 1991;25:119-25.
24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38: 518-26. (Pubitemid 36919874)
25. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCVcoinfection. Hepatology. 2006;43:1317-25. (Pubitemid 43980111)
26. Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Hematol. 2005;128:698-702. (Pubitemid 40343240)
27. Bowles KM, Cooke LJ, Richards EM, Baglin TP. Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Hematol. 2005;27:370-3. (Pubitemid 41784345)
28. Osselaer JC, Lamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem. 1997; 43:1072-6.
29. Milne DB. Copper intake and assessment of copper status. Am J Clin Nutr. 1998;Suppl67:1041S-45S.
30. Milne DB. Trace elements. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry, Fifth edition. Philadelphia: WB Saunders Company; 2001. p. 568-83.
31. Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem. 2010;43:1399-404.
32. Turecki L, Kupkova V, Mojto V, Smutny M, Uhlikova E, Vozar I. Serum activity of cholinesterase activity and proteosynthetic function of liver in patients with diabetes mellitus. Bratisl Lek Listy. 2005;106:266-9.
33. Sridar GR, Rao AA, Srinivas K, Nirmala G, Lakshmi G, Suryanarayna D, et al. Butyrylcholinesterase in metabolic syndrome. Med Hypotheses. 2010;75:648-51.
34. Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y. Sonographic assessment of fatty liver using the measurement of para-and perirenal fat thickness. J Clin Ultrasound. 2010; 38:470-4.
35. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007;13:RA124-1.
36. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes and Alzheimer's disease. Med Hypotheses. 2007;69:1272-6. (Pubitemid 47633064)
37. Puche E, Garcia-Morillas M, Garcia de la Serrana H, Mota C. Probable pseudocholinesterase induction by valproic acid, carbamazepine and phenytoin leading to increasedserum aspirin-esterase activity in epileptics. Int J Clin Pharm Res. 1989;9:309-11. (Pubitemid 20098861)
38. Tutor-Crespo MJ, Hermida J, Tutor JC. Possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels. J Clin Pharmacol. 2004;44:974-80. (Pubitemid 39096812)
39. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, et al. Effects of antiepileptic drugs on lipids, homocysteine, and c-reactive protein. Ann Neurol. 2009;65:448-56.
40. Tao TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia. 2009; 50:1579-86.
41. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47: 1136-43. (Pubitemid 44086748)
42. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology. 2010;51:603-14.
43. Nakagawa T, Muramoto Y, Hori M, Mihara S, Marubayashi T, Nakagawa K. A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease. Cin Chim Acta. 2008;398:34-8.